The GSDME Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the GSDME (DFNA5) gene in the human ovarian carcinoma A2780 cell line. This polyclonal pool provides a heterogeneous population of edited cells, each carrying gene-disrupting modifications within the GSDME locus, enabling loss-of-function studies without the constraints of clonal selection. The product serves as a robust model for investigating GSDME-dependent mechanisms, as the polyclonal nature reduces potential clonal artifacts while maintaining strong target-gene knockout efficiency across the population.
The host A2780 cell line is derived from an untreated patient with ovarian endometrioid adenocarcinoma and is widely recognized as a representative model for epithelial ovarian cancer. This adherent cell line is extensively utilized in preclinical oncology research, particularly for exploring mechanisms of chemotherapeutic response and acquired drug resistance. Its established genetic and phenotypic characteristics, including sensitivity to DNA-damaging agents, make it an ideal host for studying cell death modalities, including apoptosis and pyroptosis, which are often induced by standard-of-care chemotherapies.
GSDME functions as a critical executor of pyroptosis, a lytic and inflammatory programmed cell death. Under apoptotic stimuli, activated caspase-3 cleaves GSDME to release an N-terminal fragment that oligomerizes and inserts into the plasma membrane, forming large pores. This pore formation disrupts cellular integrity, leading to cell swelling, membrane rupture, and the release of pro-inflammatory mediators such as IL-1??, IL-18, and lactate dehydrogenase (LDH). Beyond caspase-3, upstream regulators include caspase-8, granzyme B, TNF-??, and TRAIL, often in response to chemotherapeutic drugs. GSDME activity can also interact with GSDMD and membrane lipids, positioning it at a nexus of pyroptotic, apoptotic, and necroptotic signaling. Thus, GSDME knockout provides a tool to dissect the crosstalk between these death pathways.
In the A2780 ovarian carcinoma context, GSDME-mediated pyroptosis is of particular interest due to the cell line??s application in chemosensitivity and resistance studies. Many platinum-based and other chemotherapeutic agents activate caspase-3, which can then cleave GSDME and convert a typically non-inflammatory apoptotic process into inflammatory pyroptosis. This switch may influence tumor microenvironment dynamics, immune cell recruitment, and therapeutic outcomes. Engineering polyclonal GSDME knockout A2780 populations enables researchers to directly evaluate the contribution of pyroptotic signaling to drug-induced cell death, inflammation, and resistance phenotypes without confounding genetic drift often seen in clonal lines.
The GSDME Knockout A2780 Polyclonal Cells support a broad range of research applications. They are particularly suited for investigating chemotherapy-induced pyroptosis using assays such as western blotting for GSDME cleavage fragments, LDH release for membrane permeabilization, propidium iodide uptake for pore formation, and caspase-3 activity measurements. The model also facilitates studies on inflammatory cytokine release, drug resistance mechanisms in ovarian cancer, and the role of pyroptosis in other contexts like hearing loss, where GSDME mutations are implicated. For detailed technical specifications, customization options, or pricing, please contact Ascent Research.
